NewsBite

Algorae Pharmaceuticals Ltd

Advertisement
Algorae Pharmaceuticals is using Australia’s GADI “super-computer” to generate potential new AI-drug combinations that can improve on existing, approved treatments for conditions, including heart disease.

Algorae cardiovascular drug betters beta-blockers in studies

Algorae Pharmaceuticals says its new AI-168 drug candidate shows early potential to improve on treatments to protect the heart from cardiovascular stressors.

  • Craig Nolan

Latest

Algorae Pharmaceuticals has identified 24 potential new drug combinations it plans to progress to pre-clinical evaluation.

Johnson & Johnson exec signs on for Algorae AI drug development

Johnson & Johnson exec Dr Sarah Siggins has signed on for ASX-listed Algorae Pharmaceuticals’ hunt to create drug combinations recommended by AI to tackle hard to beat diseases.

  • Craig Nolan
Algorae Pharmaceuticals has identified 24 different drug combinations put together by a super-computer using AI that it says could potentially impact some cancers.

Algorae taps AI to develop anti-cancer drug combos

Algorae Pharmaceuticals has identified 24 different drug combinations put together by a “super-computer” using AI that it says could potentially impact some cancers. The common denominator is cannabidiol.

  • James Pearson
Algorae has launched its drug-predicting “AlgoraeOS” platform, with initial results coming out better than predicted.

Algorae AI platform launch set to spark new drug discoveries

Algorae Pharmaceuticals has formally launched its drug-predicting AI platform aimed at combining previously-approved drugs to create new medical treatments.

  • James Pearson

Original URL: https://www.smh.com.au/topic/algorae-pharmaceuticals-ltd-6gw5